|Bid||2.06 x 800|
|Ask||11.33 x 1000|
|Day's Range||10.79 - 11.53|
|52 Week Range||2.58 - 16.37|
|Beta (5Y Monthly)||1.68|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 18, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.40|
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Good afternoon, ladies and gentlemen, and thank you for joining the Alpine Immune Sciences fourth-quarter 2020 financial results and corporate update conference call. With me on today's call from Alpine Immune Sciences are Executive Chairman and CEO Dr. Mitchell Gold; President and Head of Research and Development Dr. Stanford Peng; Chief Financial Officer Paul Rickey; and Chief Business Officer, Dr.
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of 0.00% and 101.39%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?